Genetic markers that predict treatment response in advanced prostate cancer
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
This project looks at whether tumor and inherited DNA changes can show which men with advanced prostate cancer are most likely to benefit from targeted drugs and immunotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11173720 on NIH RePORTER |
What this research studies
If you have advanced prostate cancer, this project would collect your tumor tissue and a blood sample to look at tumor and inherited DNA changes that might affect treatment response. Researchers at Memorial Sloan Kettering will build a large database linking genomic data with treatments and outcomes to find patterns tied to progression or benefit from PARP inhibitors and immunotherapy. The team focuses on DNA repair genes such as BRCA2 and on microsatellite instability, while also searching for other genomic signals that predict outcomes. Your medical records and samples would be analyzed to match specific genetic changes to real-world treatment results.
Who could benefit from this research
Good fit: Men with locally advanced or metastatic prostate cancer, especially those willing to provide tumor tissue and a blood sample or who have prior tumor/germline sequencing, are the ideal candidates.
Not a fit: People without prostate cancer, men with low-risk disease unlikely to need systemic therapy, or those unable/unwilling to give samples or access medical records would not directly benefit.
Why it matters
Potential benefit: If successful, the work could help personalize therapy by identifying which patients are most likely to respond to PARP inhibitors or immune checkpoint inhibitors.
How similar studies have performed: Approvals of PARP inhibitors and pembrolizumab for genomically defined prostate cancers show this approach can work for some patients, but predicting who will benefit remains imperfect.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Solit, David B. — Sloan-Kettering Inst Can Research
- Study coordinator: Solit, David B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.